07.11.16
Headquarters: Summit, NJ
twitter.com/celgene
www.celgene.com
Headcount: 7,000
Year Established: 1986
Revenues: $9,256 (+21%)
Net Income: $1,602 (-20%)
R&D: $3,697 (+52%)
TOP SELLING DRUGS
Committed to expanding a sustainable pipeline of cancer treatments Celgene Corporation acquired privately held Quanticel Pharmaceuticals, a biotechnology company focused on cancer drug discovery. Celgene bought Quanticel for $100 million upfront with an additional $385 million paid out upon research, development, and regulatory advances related to Quanticel’s research and development platform.
Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
The acquisition culminates a 2011 strategic alliance between the two companies. Over the course of the three-and-a-half year alliance, Quanticel industrialized its single-cell platform for analysis of tumor cellular content and applied it to novel target discovery and the generation of high-quality drug candidates. Multiple drug candidates from Quanticel are expected to enter the clinic in 2016.
In another deal during the year, Celgene expanded its inflammation and immunology portfolio with the acquisition of Receptos for roughly $7.2 billion. The acquisition expands its inflammation and immunology portfolio with the addition of Ozanimod, an oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P), to its pipeline of potential disease-altering medicines and investigational compounds.
Clinical studies of Ozanimod have demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile.
To develop small molecule therapeutics in oncology, inflammation and immunology and immune-oncology, Celgene partnered with Nurix during the year. In an R&D alliance set up to discover and develop therapeutics for ulcerative colitis and Crohn’s disease, Celgene teamed up with Inception IBD, a Québec-based biotechnology company, and Inserm Transfert Initiative, created under the initiative of Inserm, the French National Institute of Health and Medical Research.
twitter.com/celgene
www.celgene.com
Headcount: 7,000
Year Established: 1986
Revenues: $9,256 (+21%)
Net Income: $1,602 (-20%)
R&D: $3,697 (+52%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Revlimid | multiple myeloma, mantle cell lymphoma | $5,801 | 17% |
Abraxane | breast, lung, pancreatic cancer | $968 | 14% |
Pomalyst | multiple myeloma | $983 | 45% |
Vidaza | myelodysplastic syndrome | $591 | -4% |
Otezla | psoriasis | $472 | n/a |
Committed to expanding a sustainable pipeline of cancer treatments Celgene Corporation acquired privately held Quanticel Pharmaceuticals, a biotechnology company focused on cancer drug discovery. Celgene bought Quanticel for $100 million upfront with an additional $385 million paid out upon research, development, and regulatory advances related to Quanticel’s research and development platform.
Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
The acquisition culminates a 2011 strategic alliance between the two companies. Over the course of the three-and-a-half year alliance, Quanticel industrialized its single-cell platform for analysis of tumor cellular content and applied it to novel target discovery and the generation of high-quality drug candidates. Multiple drug candidates from Quanticel are expected to enter the clinic in 2016.
In another deal during the year, Celgene expanded its inflammation and immunology portfolio with the acquisition of Receptos for roughly $7.2 billion. The acquisition expands its inflammation and immunology portfolio with the addition of Ozanimod, an oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P), to its pipeline of potential disease-altering medicines and investigational compounds.
Clinical studies of Ozanimod have demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile.
To develop small molecule therapeutics in oncology, inflammation and immunology and immune-oncology, Celgene partnered with Nurix during the year. In an R&D alliance set up to discover and develop therapeutics for ulcerative colitis and Crohn’s disease, Celgene teamed up with Inception IBD, a Québec-based biotechnology company, and Inserm Transfert Initiative, created under the initiative of Inserm, the French National Institute of Health and Medical Research.